Doug Williamson

Doug Williamson, M.D., is the Executive Vice President of Research and Development and has been with Acadia since January 2023.

Dr. Williamson has almost 30 years of scientific, clinical and medical experience primarily focused on neuroscience. Prior to joining Acadia, he served as Chief Medical Officer at Avadel Pharmaceuticals. Prior to that, he was Senior Vice President, Head of U.S. R&D and Deputy Global Chief Medical Officer at Lundbeck. In this role, he led a transformation of the U.S. R&D organization and oversaw multiple cross-functional teams across clinical development and operations, medical affairs, health outcomes, pharmacovigilance, clinical pharmacology and regulatory affairs. Prior to Lundbeck, he served as Vice President, Global Head of Therapeutic Area Leadership at Parexel International, where he was the functional head of the medical group across all therapeutic areas. Earlier in his career, Dr. Williamson held multiple roles at Eli Lilly and Company in late-stage clinical development and medical affairs, in addition to serving as Head of Early Phase Clinical Development, Neuroscience, where he oversaw the clinical development of all novel molecules in the psychiatry, pain and neurodegeneration portfolio.

Dr. Williamson earned his medical degree from Edinburgh University in Scotland. He is a Member of the Royal College of Psychiatrists.